Announced details
We have entered into a joint development agreement and are jointly developing Pegevongitide (AV-001).
A Canadian privately held, clinical-stage biopharmaceutical company. Its headquarters and research facilities are in Toronto, Canada, and it also has operations in Raleigh, North Carolina, United States. Its CEO is Dr. Brian E. Jahns. The company is developing therapies targeting vascular leakage.
NATO Support and Procurement Organisation (NSPA) headquarters in Capellen, Luxembourg (conference venue)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Pegevongitide（AV-001）, Tie2 receptor agonist (AV-001) |
| Counterparty | Vasomune Therapeutics, Inc. |
| Counterparty overview | A Canadian privately held, clinical-stage biopharmaceutical company. Its headquarters and research facilities are in Toronto, Canada, and it also has operations in Raleigh, North Carolina, United States. Its CEO is Dr. Brian E. Jahns. The company is developing therapies targeting vascular leakage. |
| Relationship with the Company | We have entered into a joint development agreement and are jointly developing Pegevongitide (AV-001). |
| Launch date | 28 to 29 September 2026 (scheduled presentation dates at the NATO NSPA CBRN Conference) |
| Applicable area | Medical countermeasures for chemical, biological, radiological and nuclear (CBRN) threats, ARDS (acute respiratory distress syndrome), Hemorrhagic shock, Trauma, Shock following severe burns, Military medicine and public health |
| Location | NATO Support and Procurement Organisation (NSPA) headquarters in Capellen, Luxembourg (conference venue) |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To engage with military and government officials and leaders in the scientific community and discuss dual-use medical technologies that can help improve survival rates among military personnel and strengthen civilian emergency medical response capabilities.